Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601553 | 0.91 | MMP9 (0.40) | TACR1MC4RMC3RMC1RMMP9 | |
| SCHEMBL6601809 | 0.90 | TACR1 (0.43) | TACR1MMP9MMP8 | |
| SCHEMBL27477312 | 0.90 | TACR1 (0.43) | TACR1MMP9MMP8 | |
| SCHEMBL6601864 | 0.89 | TACR1 (0.39) | TACR1MC4RMC3RMC1RPLG | |
| SCHEMBL6600882 | 0.89 | MMP9 (0.42) | TACR1MC4RMC3RMC1RMMP9 | |
| SCHEMBL6601359 | 0.88 | MEN1 (0.42) | TACR1CAPN1 | |
| SCHEMBL6599943 | 0.83 | CTSS (0.48) | TACR1MMP9MMP8 | |
| SCHEMBL6599942 | 0.83 | CTSS (0.48) | TACR1MMP9MMP8 | |
| SCHEMBL6602292 | 0.83 | SLC6A4 (0.41) | TACR1 | |
| SCHEMBL6601272 | 0.82 | MEN1 (0.42) | TACR1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0805816-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-07-28 | — | — | EP | claimed |
| EP-0805816-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022997-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-08-01 | — | — | WO | claimed |
| EP-2389941-A1 | Growth-hormone secretagogues | Elixir Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20080261873-A1 | Growth-Hormone Secretagogues | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-0805816-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-07-28 | — | — | EP | disclosed |
| US-6350767-B1 | GROWTH HORMONE RELEASE STIMULANT | NOVO NORDISK A/S (DK) | 2002-02-26 | — | — | US | disclosed |
| US-6013658-A | ANIMAL GROWTH REGULATORS | NOVO NORDISK A/S (DK) | 2000-01-11 | — | — | US | disclosed |
| EP-0907374-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261873-A1 | Growth-Hormone Secretagogues | GHSR, GHRHR, GIPR | TACR1 393/4885MC4R 83/4885MC3R 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.